Skip to main content
IMVT logo
IMVT
(NASDAQ)
Immunovant, Inc.
$39.37-- (--)
Loading... - Market loading

Immunovant (IMVT) Cash Flow Statement

Operating, investing, and financing activities with annual and quarterly data.

Immunovant Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Immunovant, Inc. (IMVT) - Annual data in millions USD
BreakdownFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018
Operating Activities
Net Income-505.61-413.84-259.34-210.96-156.73-107.43-66.39-28.60-136.74
Depreciation & Amortization0.410.380.230.190.130.070.020.010.00
Stock Based Compensation55.7249.4941.1232.3034.2418.826.961.311.81
Change in Working Capital42.06-12.032.63-10.8515.144.574.81-0.471.44
Change in Accounts Receivable-1.402.97-4.5612.23-11.63-0.60-0.080.000.00
Change in Accounts Payable-10.2510.685.78-16.9716.251.250.970.000.00
Change in Other Working Capital53.72-25.691.411.131.13-0.053.92-0.471.44
Other Operating Activities0.100.131.131.131.110.651.24-0.795.19
Net Cash from Operating Activities-407.31-375.87-214.23-188.19-106.11-83.33-53.36-28.55-128.30
Investing Activities
Capital Expenditures-0.01-0.76-0.36-0.20-0.25-0.21-0.03-0.050.00
Net Cash from Investing Activities-0.01-0.76-0.36-0.20-0.25-0.21-0.03-0.050.00
Financing Activities
Debt Repayment0.000.000.000.000.00-3.1937.910.000.00
Common Stock Issued596.26450.00472.7570.50200.13387.540.000.000.00
Other Financing Activities-0.504.49-0.32-0.27200.13-1.24109.0735.58128.30
Net Cash from Financing Activities595.76454.49472.4370.89200.13383.11146.9735.58128.30
Summary
Effect of Forex Changes on Cash-0.300.750.990.22-0.090.000.000.000.00
Net Change in Cash188.1478.61258.83-117.2993.67299.5893.596.990.00
Cash at Beginning of Period713.97635.37376.53493.82400.15100.576.990.000.00
Cash at End of Period902.11713.97635.37376.53493.82400.15100.576.990.00
Free Cash Flow-407.32-376.63-214.59-188.39-106.37-83.54-53.39-28.60-128.30
Supplemental Disclosures
Income Taxes Paid0.001.200.510.000.000.170.000.000.00

Frequently Asked Questions About Immunovant Cash Flow

What is a cash flow statement?

A cash flow statement tracks the actual cash moving in and out of a company during a period. It's divided into three sections: operating activities (core business), investing activities (assets and investments), and financing activities (debt and equity). Unlike the income statement, it shows real cash rather than accounting profits.

What is operating cash flow?

Operating cash flow is the cash generated from a company's core business operations. It adjusts net income for non-cash items like depreciation and changes in working capital. Strong operating cash flow indicates the business can fund operations without external financing.

What is free cash flow (FCF)?

Free cash flow is operating cash flow minus capital expenditures. It represents the cash available for dividends, share buybacks, debt repayment, or reinvestment. FCF is considered one of the most important metrics for evaluating a company's financial health.

What are capital expenditures?

Capital expenditures (CapEx) are funds spent on acquiring or maintaining physical assets like property, equipment, and technology. CapEx appears in the investing activities section and is subtracted from operating cash flow to calculate free cash flow.

How is IMVT's cash generation trending?

Review Immunovant's operating cash flow and free cash flow figures in the quarterly and annual data above. Consistent growth in operating cash flow relative to net income indicates high-quality earnings.

These financial metrics are calculated using cash flow data. Learn how each metric works and screen stocks by them.